Phys Vivas · haematological
Myeloproliferative Neoplasms — Viva Defence
DCE viva defence for Myeloproliferative Neoplasms.
On this page & tools
Target exams
Myeloproliferative Neoplasms Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Myeloproliferative Neoplasms. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
Short case
Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]
References
- [1]Rivière E, Guy A, Mansier O, Mediavilla C, et al. Autoimmunity and peginterferon therapy for polycythemia vera Hemasphere, 2026.PMID 42465525
- [2]Hu LJ, Yang WY [Progress in the study of polycythemia vera in children] Zhongguo Dang Dai Er Ke Za Zhi, 2026.PMID 42457335
- [3]Gašljević G, Dora P, Grčar-Kuzmanov B, Urdih T, et al. ARAF mutated langerhans cell histiocytosis developed on the background of ARAF/JAK2 mutated polycythaemia vera: evidence of branching evolution from the same progenitor cell. A case report and literature review Ann Hematol, 2026.PMID 42448959
- [4]Gerds AT, Gotlib J, Abdelmessieh P, Ali H, et al. NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026 J Natl Compr Canc Netw, 2026.PMID 42425157
- [5]Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association [Chinese guidelines on the diagnosis and treatment of adult essential thrombocythemia (2026)] Zhonghua Xue Ye Xue Za Zhi, 2026.PMID 42409729
- [6]Leiva O, Liu OC, Ferrante M, Katsadouros VP, et al. Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know Semin Hematol, 2026.PMID 42243010
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922